PubMed Health⌕ Search

Biomedical subjects

S Katsumi

Publications and source records attributed to S Katsumi.

14 recordsLinked to original sources
PubMed2000

Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.

We describe a patient with systemic lupus erythematosus (SLE) associated with topoisomerase I (topo I, Scl-70) antibody, a specific marker for systemic sclerosis (SSc). SSc patients who produce this antibody have severe cutaneous and visceral involvement, and eventually have a poor prognosis. It is rare to find this antibody in patients with other collagen diseases. Only four SLE patients have been reported in the English language literature who were topo I antibody-positive but had no clinical evidence of scleroderma. The serum of our patient with SLE had precipitating topo I antibody from the onset of his disease. Twelve years after the onset of SLE, he developed proximal scleroderma and pulmonary fibrosis. This case reconfirms the prognostic significance of topo I antibody as a predictive marker, and indicates that SLE patients with topo I antibody require careful follow-up for future development of scleroderma.

Adult↗
PubMed1988

[Enhancement of antitumor effect of MMC on Walker 256 by intra-arterial administration of noradrenaline in hyperthermia].

We performed a study of hyperthermia while injecting 0.05% of Noradrenaline following MMC for 10 minutes into the feeding artery of Walker-256 carcinosarcomas implanted 6 days earlier into the s.c. dorsum side of hindpaw of Wistar rats. The tumor growth rates on the 6th day after treatment by warning tumor in hot water (40 degrees C, 44 degrees C) for 10 minutes with or without Noradrenaline, were 0.7 +/- 0.6, 2.1 +/- 0.9 (40 degrees C) and 0.2 +/- 0.3, 0.0 +/- 0.0 (44 degrees C), respectively. The data suggested that tumor ischemia induced by a vasoconstrictive drug may enhance the antitumor effect in low grade warning therapy (40 degrees C). An injection of warmed physiological saline (50 degrees C) may heat the tumor vessels on the tumor surface and showed enhanced antitumor effects as a from of hyperthermia. The target area of the tumor for hyperthermia can be considered to be the tumor vessels on the tumor surface.

Animals↗
PubMed1987

[Thermochemotherapy of unresectable pancreatic carcinoma (hot water and intra-arterial chemotherapy using noradrenaline)].

A 86-year-old man with unresectable pancreatic carcinoma was treated with thermochemotherapy. In most of the body and tail affected by the tumor, which did not show any cytotoxic damage after intraarterial chemotherapy, an enhanced antitumor effect was achieved by hyperthermia, which heated the tumor using hot water in a balloon placed on the pancreas, and which was delivered through a vinyl tube leading out of the body for 40 minutes while administration of antitumor agents mixed with noradrenaline was simultaneously given into the celiac artery. In this case, we observed that using noradrenaline with contrast material injected into the celiac artery it was possible to delineate the tumor area by computed tomography of the pancreas.

Aged↗
PubMed1985

[Intra-arterial chemotherapy with nor-adrenaline. Experimental study 1 (enhancement of anti-tumor effect and tumor vessels)].

We have performed studies to observe whether the administration of nor-adrenaline during intraarterial chemotherapy has the possibility of increasing the permeability of tumor vessels and thus enhancing the anti-cancer effects. The tumor model was Walker-256, which was implanted into the dorsum side of the hindpaw of Wistar rats. Tumors were divided into those in which tumor vessels were not apparent after two days (D-2 group), and those in which vessels appeared after four and six days (D-4 and 6 group). Vascular permeability within the tumors was measured quantitatively using Evans Blue (EB) uptake volume in the tumor after intraarterial injection of 10 mg of EB with nor-adrenaline (nor-ad group) or the same dose of EB alone (control group). The mean values for the nor-ad group/control groups were calculated as the permeability activity of vessels enhanced by administration of nor-adrenaline in the D-2 to 6 group. The permeability activity of the D-2 group was 0.8, while that of the D-4 and 6 group was 2.5. The 90-day survival ratio was not improved in the D-2 group (P greater than 0.1), but was improved in the D-4 and 6 group (P less than 0.005) by intraarterial administration of 0.5 mg/kg of MMC with 2 mcg of nor-adrenaline, compared with the same dose of MMC alone. Therefore, the use of nor-adrenaline in intraarterial chemotherapy was observed to increase the permeability of tumor vessels and improve the treatment results.

Animals↗
PubMed1985

[Intra-arterial infusion chemotherapy combine with noradrenalin administration (an improved antitumor effect using a cancerous blood vessel].

We have performed experimental and clinical studies to observe whether higher concentrations of drugs are selectively delivered into tumor tissues through the tumor vessels and improved chemotherapy results were obtained by using noradrenaline in intraarterial chemotherapy. Noradrenaline administered into the tumor-feeding artery may enhance drug delivery into the tumor tissue and show improved chemotherapy results on Walker-256 formed tumor vessels. These advantages of using vasoconstrictive agents may be considered to be derived from the high injection pressure caused by increased vascular resistance and various other factors induced in abnormal microcirculation of the tumor vessels. MMC concentration in Walker-256 (weight 0.2 to 0.39 g) after intraarterial administration of 10 mg of MMC in 2.5 ml of physiological saline were 2.20 +/- 1.26 mcg/g (n = 11) in the noradrenaline group and 0.52 +/- 0.22 mcg/g (n = 13) in the MMC alone group. The 90-day survival ratio for intraarterial injection of 0.25 mg/kg of MMC and 2 mcg of noradrenaline was 42.9% (6/14), a result equivalent to a dose range of between 0.50 mg/kg and 0.75 mg/kg without the use of any vasoactive drug. The median survival periods for stomach cancer (Stage 4) after non-radical surgery by means of intraarterial chemotherapy with and without noradrenaline were, respectively, 12 months (n = 8) and 5.8 months (n = 6), with statistical significance (P greater than 0.05). Effective histological changes estimated microscopically by Takahashi's criteria of preoperative treatment in 31 stomach cancer patients were found in 11 patients (36.7%) with primary tumor and 12 patients (52.2%) with metastatic lymph nodes. A partial response rate of 54.5 (6/11) for hepatic tumor (Stages 3 to 4 according to was achieved with the use of the Ariel's classification) following regimen: intravenous injection of 70 mg/body of CDDP on the first day, followed by intraarterial injection of 0.1 to 0.4 mg/kg of MMC and 0.1 to 0.6 mg/kg of ADM together with 0.3 to 1.0 mg of noradrenaline in 40 to 100 ml of physiological saline for 3 to 20 minutes within one week after the first treatment. Most of the complications were due to hemorrhage from ulceration of the intestinal canal because of mucosal damage caused by the high concentration of anti-cancer drugs induced by noradrenaline. Decrease of hemoglobin of more than 1.0 g/dl was found in 19 out of 31 patients (61.3%) who received no treatment for bleeding, and in one out of 13 patients (7.7%) who was administered 200 mg of cimetidine twice a day for one week.

Animals↗